Training Local Leaders to Prevent and Reduce Domestic Violence Evidence From Peru
Launched by DUKE UNIVERSITY · Apr 12, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Leaders in Action (LIA) trial is studying ways to reduce domestic violence, specifically Intimate Partner Violence (IPV), in Peru by changing social attitudes and norms around violence. The program includes two different approaches: one where community health volunteers visit households to provide training, and another where small groups of women meet for educational sessions. By comparing these two methods, the trial aims to find out which is more effective in preventing violence and changing harmful ideas about gender roles.
To participate in the trial, women aged 18-59 who live with male partners and have been identified as at risk for IPV may be eligible. Additionally, male partners of these women and selected village leaders are also included. Participants can expect to receive support through training and education aimed at creating a safer community. This study not only aims to provide valuable insights for improving domestic violence prevention programs but also to understand how these interventions can be effectively implemented and sustained in the future.
Gender
ALL
Eligibility criteria
- • Eligibility to receive the initial census: Women between the ages of 18-59 in 2022, who lived with a male partner, and who were permanent residents in villages from our sample (defined as living in the village for at least 4 months of the year).
- Eligibility to be part of the targeted sample:
- • Women identified to be at risk of suffering from IPV in the census, who as a result, also received a baseline survey.
- • In 50 percent of the treatment villages chosen at random, an additional 30% of women randomly selected from the census.
- • Male partners of women in the targeted sample.
- • Across a sub-sample of 94 treatment villages chosen at random, 1 village leader. Specifically, we identified two village leaders, one male and one female, and randomly selected which of the genders was selected for targeting. This resulted in 50 women leaders and 44 men leaders, and their partners.
- Eligibility for the endline survey sample:
- • We plan to interview all men, women, and village leaders in our targeted sample.
- • We will also interview 4 additional women per village who were eligible to receive the initial census but were not part of the targeted sample, as well as their male partners, to measure spillover effects.
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lima, , Peru
Patients applied
Trial Officials
Erica Field, PhD
Principal Investigator
Duke University
Livia Schubiger, PhD
Principal Investigator
University of Oxford
Ursula Aldana, PhD
Principal Investigator
Instituto de Estudios Peruanos
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials